EP
ANIP icon

Essential Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Essential Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248 Hold
3
– – ﹤0.01% 2603
2026
Q1 		$231 Hold
3
– – ﹤0.01% 2582
2025
Q4 		$237 Hold
3
– – ﹤0.01% 2398
2025
Q3 		$275 Hold
3
– – ﹤0.01% 2341
2025
Q2 		$196 Buy
+3
New +$195 ﹤0.01% 1949

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's ANIP Position: Q2 2026 in Review

Essential Partners held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 3 shares worth $248. The position accounts for ﹤0.01% of the portfolio, ranked #2603.

Essential Partners first reported a position in ANIP in Q2 2025 and has held it in 5 quarters since. The position peaked at $275 in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Essential Partners held 3 shares of ANI Pharmaceuticals worth $248 as of Q2 2026.
  • Essential Partners left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2603 holding.
  • Essential Partners first reported a position in ANI Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's ANI Pharmaceuticals position peaked at $275 in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.